Base de dados : LILACS
Pesquisa : G02.111.570.080.689.330 [Categoria DeCS]
Referências encontradas : 5 [refinar]
Mostrando: 1 .. 5   no formato [Detalhado]

página 1 de 1

  1 / 5 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-968270
Autor: Ramos, Silvia; Straw, Cecilia; Almada, Cecilia; Scheneider, Marcela; Pesce, Veronica; Mignini, Luciano; Tabares, Gonzalo; Robles, Nadia; Romero, Ivana; Morretto, Victoria.
Título: Barreras y facilitadores en las trayectorias de mujeres con cáncer de mama usuarias de hospitales públicos / Barriers And Facilitators of Health Seeking Behavior Among Women with Breast Cancer Users of Public Hospitals
Fonte: Rev. argent. salud publica;9(36):14-21, 2018.
Idioma: es.
Resumo: El cáncer de mama (CM) es el segundo más común en el mundo y el más frecuente entre las mujeres. La incidencia varía entre regiones. Además, el CM es la quinta causa de muerte por cáncer a nivel mundial, la más frecuente en las regiones menos desarrolladas y la segunda en las más desarrolladas y en Sudamérica. En Argentina, registra las mayores tasas de incidencia y mortalidad entre las mujeres. OBJETIVOS: Comprender los motivos de las demoras, las consecuencias y las estrategias usadas por mujeres con diagnóstico de CM para afrontar barreras durante sus trayectorias de atención. MÉTODOS: Se realizó un estudio descriptivo transversal con abordaje cualitativo, basado en mujeres diagnosticadas con CM en dos hospitales públicos de la provincia de Santa Fe. Se efectuaron entrevistas semiestructuradas, que fueron grabadas previo consentimiento informado. Se utilizó el programa Atlas-ti (V.7.2) para el análisis del material. RESULTADOS: Se identificaron barreras a nivel personal (cuestiones financieras, creencias de las pacientes), interpersonal (cuestiones laborales, responsabilidad familiar, comunicación médico-paciente) y del sistema de salud (organización de servicios, calidad de atención). CONCLUSIONES: La investigación aporta evidencia para comprender las barreras que enfrentan las mujeres diagnosticadas con CM y muestra las oportunidades para implementar la estrategia de navegación de pacientes a fin de reducir o mitigar las demoras en la atención
Descritores: Neoplasias da Mama
Elementos Facilitadores Genéticos
Limites: Humanos
Tipo de Publ: Artigo Clássico
Responsável: AR650.1 - Biblioteca


  2 / 5 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-641008
Autor: Picanço-Castro, V; Russo-Carbolante, E. M. S; Fontes, A. M; Fernandes, A. C; Covas, D. T.
Título: An enhancer/promoter combination strengthens the expression of blood-coagulation factor VIII in non-viral expression vectors
Fonte: Genet. mol. res. (Online);7(2):314-325, 2008. tab, ilus.
Idioma: en.
Resumo: We explored the potential of fusion of hepatic locus control region 1 (HCR-1) with HCR-2 to express B-domain-deleted human factor VIII (FVIII) in four cell lines. B-domain-deleted human FVIII expression was controlled by HCR-1/HCR-2, followed by liver specific and ubiquitous promoters. Chimera enhancer HCR-1/HCR-2, followed by cytomegalovirus (CMV) promoter, gave 2-fold more FVIII expression in all cell lines (105.6 ± 2.8 for Hek-293, 68.8 ± 3.8 for HepG2, 34.8 ± 1.3 for CHO, and 27.2 ± 1.6 ng-mL-1-106 cells-1 for L.N.) when compared to the vector with CMV alone (54.8 ± 3.3 for Hek-293, 32.4 ± 1.2 for HepG2, 18.6 ± 1.1 for CHO, and 10.1 ± 1.7 ng-mL-1-106 cells-1 for L.N.). Elongation factor 1-α gene and human CMV promoters were more efficient than the promoters from the human α-1-antitrypsin gene, and fviii was less efficient in hepatic cell lines. HCR-1/HCR-2, followed by strong promoters, increases FVIII expression in vitro. Our results underscore the importance of cis sequences for enhancing in vitro FVIII expression; this may be helpful for designing new strategies to improve heterologous expression systems.
Descritores: Elementos Facilitadores Genéticos/genética
Fator VIII/genética
Regiões Promotoras Genéticas/genética
Vetores Genéticos/genética
-Linhagem Celular
Linhagem Celular Tumoral
Células CHO
Cricetinae
Cricetulus
Citomegalovirus/genética
Fator VIII/metabolismo
Imuno-Histoquímica
Microscopia de Fluorescência
Plasmídeos
Proteínas Recombinantes de Fusão/genética
Proteínas Recombinantes de Fusão/metabolismo
Proteínas de Fluorescência Verde/genética
Proteínas de Fluorescência Verde/metabolismo
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Limites: Humanos
Animais
Responsável: BR26.1 - Biblioteca Central


  3 / 5 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: lil-618070
Autor: Harwansh, Ranjit Kumar; Patra, Kartik Chandra; Pareta, Surendra Kumar; Singh, Jagadish; Rahman, Mohammed Akhlaquer.
Título: Nanoemulsions as vehicles for transdermal delivery of glycyrrhizin
Fonte: Braz. j. pharm. sci;47(4):769-778, Oct.-Dec. 2011. ilus, graf, tab.
Idioma: en.
Resumo: The present investigation aims to evaluate an isotropic and thermodynamically stable nanoemulsion formulation for transdermal delivery of glycyrrhizin (GZ), with minimum surfactant and cosurfactant (Smix) concentrations that could improve its solubility, permeation enhancement, and stability. Pseudo-ternary phase diagrams were developed and various nanoemulsion formulations were prepared using soyabean oil as oil, Span 80, Brij 35 as a surfactant and isopropyl alcohol as a cosurfactant. Nanoemulsion formulations that passed the thermodynamic stability tests were characterized for pH, viscosity and droplet size using a transmission electron microscopy. The transdermal ability of glycyrrhizin through human cadaver skin was determined using Franz diffusion cells. The in vitro skin permeation profile of the optimized nanoemulsion formulation (NE2) was compared to that of conventional gel. A significant increase in permeability parameters such as steady-state flux (Jss) and permeability coefficient (Kp) was observed in the optimized nanoemulsion formulation (NE2), which consisted of 1 percent wt/wt of mono ammonium glycyrrhizinate (MAG), 32.4 percent Span 80, 3.7 percent Brij 35, 10 percent isopropyl alcohol, 46.5 percent soyabean oil and 6.4 percent distilled water. No obvious skin irritation was observed for the studied nanoemulsion formulation (NE2) or the gel. The results indicated that nanoemulsions are promising vehicles for transdermal delivery of glycyrrhizin through human cadaver skin, without the use of additional permeation enhancers, because excipients of nanoemulsions act as permeation enhancers themselves.

O objetivo da investigação é avaliar uma nanoemulsão isotrópica termodinamicamente estável para a administração transdérmica da glicirrizina (GZ), com concentrações mínimas de tensoativo e co-tensoativo (Smix), que poderiam melhorar a sua solubilidade, a permeação e a estabilidade. Os diagramas pseudo-ternários de fase foram desenvolvidos e diversas nanoemulsões foram preparadas com óleo de soja como óleo, Span 80, Brij 35 como tensoativos e álcool isopropílico como co-tensoativo. As nanoemulsões que passaram por testes de estabilidade termodinâmica foram caracterizadas por pH, viscosidade, tamanho de gota e microscopia eletrônica de transmissão. A capacidade transdérmica da glicirrizina em passar através da pele de cadáver humano foi determinada por células de difusão de Franz. O perfil in vitro de permeação cutânea da formulação otimizada (NE2) foi comparada com a de gel convencional. Observou-se aumento significativo nos parâmetros de permeabilidade, como fluxo de equilíbrio (JSS) e coeficiente de permeabilidade (Kp) na formulação otimizado (NE2), que consistiu de 1 por cento wt/wt de monoglicirrizinato de amônio (MAG), 32,4 por cento de Span 80, 3,7 por cento de Brij 35, 10 por cento de álcool isopropílico, 46,5 por cento de óleo de soja e 6,4 por cento de água destilada. Não se observou irritação óbvia da pele para as nanoemulsões estudadas (NE2) ou de gel. Os resultados indicaram que nanoemulsões são promissores veículos para a administração transdérmica de glicirrizina através da pele de cadáveres humanos, sem o uso adicional de promotor de permeação, porque excipientes de nanoemulsões atuam como promotores de permeação.
Descritores: Administração Cutânea
Anti-Inflamatórios/farmacocinética
Ácido Glicirrízico/farmacocinética
-Elementos Facilitadores Genéticos
Técnicas In Vitro/estatística & dados numéricos
Nanotecnologia
Tensoativos/farmacocinética
Responsável: BR1.1 - BIREME


  4 / 5 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-228257
Autor: Harms, J. S; Oliveira, S. C; Splitter, G. A.
Título: Regulation of transgene expression in genetic immunization
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;32(2):155-62, feb. 1999. tab, graf.
Idioma: en.
Conferência: Apresentado em: International Symposium The Third Revolution on Vaccines: DNA Vaccines, Belo Horizonte, Nov. 3-7 1997.
Projeto: University of Wisconsin. Robert Draper Technology Innovation Found.
Resumo: The use of mammalian gene expression vectors has become increasingly important for genetic immunization and gene therapy as well as basic research. Essential for the success of these vectors in genetic immunization is the proper choice of a promoter linked to the antigen of interest. Many genetic immunization vectors use promoter elements from pathogenic viruses including SV40 and CMV. Lymphokines produced by the immune response to proteins expressed by these vectors could inhibit further transcription initiation by viral promoters. Our objective was to determine the effect of IFN-g on transgene expression driven by viral SV40 or CMV promoter/enhancer and the mammalian promoter/enhancer for the major histocompatibility complex class I (MHC I) gene. We transfected the luciferase gene driven by these three promoters into 14 cell lines of many tissues and several species. Luciferase assays of transfected cells untreated or treated with IFN-g indicated that although the viral promoters could drive luciferase production in all cell lines tested to higher or lower levels than the MHC I promoter, treatment with IFN-g inhibited transgene expression in most of the cell lines and amplification of the MHC I promoter-driven transgene expression in all cell lines. These data indicate that the SV40 and CMV promoter/enhancers may not be a suitable choice for gene delivery especially for genetic immunization or cancer cytokine gene therapy. The MHC I promoter/enhancer, on the other hand, may be an ideal transgene promoter for applications involving the immune system
Descritores: Regulação da Expressão Gênica
Vetores Genéticos
Transgenes
Vacinas de DNA
-Citomegalovirus
Elementos Facilitadores Genéticos
Genes MHC Classe I
Luciferases
Regiões Promotoras Genéticas
Vírus 40 dos Símios
Tipo de Publ: Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME


  5 / 5 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Cândido, A. L
Texto completo
Id: lil-228256
Autor: Azevedo, V; Levitus, G; Miyoshi, A; Cândido, A. L; Goes, A. M; Oliveira, S. C.
Título: Main features of DNA-based immunization vectors
Fonte: Braz. j. med. biol. res = Rev. bras. pesqui. méd. biol;32(2):147-53, feb. 1999. ilus.
Idioma: en.
Conferência: Apresentado em: International Symposium The Third Revolution on Vaccines: DNA Vaccines, Belo Horizonte, Nov. 3-7 1997.
Resumo: DNA-based immunization has initiated a new era of vaccine research. One of the main goals of gene vaccine development is the control of the levels of expression in vivo for efficient immunization. Modifying the vector to modulate expression or immunogenicity is of critical importance for the improvement of DNA vaccines. The most frequently used vectors for genetic immunization are plasmids. In this article, we review some of the main elements relevant to their design such as strong promoter/enhancer region, introns, genes encoding antigens of interest from the pathogen (how to choose and modify them), polyadenylation termination sequence, origin of replication for plasmid production in Escherichia coli, antibiotic resistance gene as selectable marker, convenient cloning sites, and the presence of immunostimulatory sequences (ISS) that can be added to the plasmid to enhance adjuvanticity and to activate the immune system. In this review, the specific modifications that can increase overall expression as well as the potential of DNA-based vaccination are also discussed
Descritores: Vetores Genéticos
Vacinas de DNA
-Elementos Facilitadores Genéticos
Regiões Promotoras Genéticas
Tipo de Publ: Revisão
Research Support, Non-U.S. Gov't
Responsável: BR1.1 - BIREME



página 1 de 1
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde